Whitehawk Therapeutics Inc
HealthcareNASDAQ:WHWK · NASDAQ Global Market
+$0.10 today
Vol 0.16M · Avg 0.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.1%
avg -22.2%
ROIC
-83.9%
avg 247.7%
ROA
-13.7%
avg -49.8%
Analysis
ROA is currently the strongest return metric at -13.7% versus its period average of -49.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David J. Lennon | President, Chief Executive Officer & Director | $1.07M | — | 55 | $569,643.00 | 1.15% |
Scott Giacobello | Chief Financial Officer, Treasurer, Investor Relations & Corporate Communications | $721,561.00 | — | 56 | $333,489.00 | 0.67% |
Bryan Ball | Chief Technical Operations Officer | $687,455.00 | — | 56 | $448,126.00 | 0.91% |
Neil Desai | Founder & Director | $40,000.00 | — | 61 | $40,006.00 | 0.08% |
David Dornan | Chief Scientific Officer | — | — | 48 | $569,643.00 | 1.15% |
Margaret Han Dugan | Chief Medical Officer | — | — | 69 | $19,132.00 | 0.04% |
Stephen Rodin | Senior Vice President of Legal & General Counsel | — | — | 50 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$2.58M
Net Sentiment
$2.58M
Net selling
Most Active
Lennon David James
6 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $2.58M over the last 12 months. That adds up to net selling of $2.58M. Lennon David James was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +18.7% | -2.4% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.7% over three years. Forward estimates point to Revenue at -2.4% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Clene Inc.
NASDAQ:CLNN
$60.20M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages WHWK?
Whitehawk Therapeutics Inc (WHWK) lists 7 active executives. The top listed executive is Neil Desai, Founder & Director.
Are WHWK insiders buying or selling?
Recent insider activity shows net buying of $10.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.